Habib Dable - Acceleron Pharma President CEO, Director
CEO
Mr. Habib J. Dable is President, Chief Executive Officer, Director of the Company. He has served as our Chief Executive Officer and President and a member of our Board of Directors since December 2016. Mr. Dable is a seasoned pharmaceutical executive, with experience in maximizing the potential of new therapies and successfully implementing innovative U.S. and global product launches. Since 1994, Mr. Dable has served in roles of increasing responsibility at Bayer AG, serving since October 2015 as the President of Pharmaceuticals for Bayer in the U.S. From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology Global Launch Team Head for EYLEA since 2016.
| Age | 47 |
| Tenure | 8 years |
| Phone | 617 649-9200 |
| Web | www.acceleronpharma.com |
Acceleron Pharma Management Efficiency
The company has return on total asset (ROA) of (16.73) % which means that it has lost $16.73 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.16) %, meaning that it created substantial loss on money invested by shareholders. Acceleron Pharma's management efficiency ratios could be used to measure how well Acceleron Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.43 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Acceleron Pharma has a current ratio of 14.51, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Acceleron Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Acceleron Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acceleron Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acceleron to invest in growth at high rates of return. When we think about Acceleron Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | CEO Age | ||
| John Plueger | Air Lease | 70 | |
Management Performance
| Return On Equity | -29.16 | |||
| Return On Asset | -16.73 |
Acceleron Pharma Leadership Team
Elected by the shareholders, the Acceleron Pharma's board of directors comprises two types of representatives: Acceleron Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acceleron. The board's role is to monitor Acceleron Pharma's management team and ensure that shareholders' interests are well served. Acceleron Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acceleron Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean George, Independent Director | ||
| Terrance McGuire, Independent Director | ||
| Matthew Sherman, Senior Vice President Chief Medical Officer | ||
| Robert Zeldin, Chief Medical Officer | ||
| Christopher Rovaldi, Senior Vice President Program Management and Operations | ||
| Richard Pops, Independent Director | ||
| Ravindra Kumar, Chief Scientific Officer, Vice President | ||
| Thomas McCourt, Director | ||
| Francois Nader, Director | ||
| John Quisel, Vice President General Counsel, Secretary | ||
| Tom Maniatis, Independent Director | ||
| John Knopf, Founder, CEO and President and Director | ||
| Steven Ertel, COO and Executive VP | ||
| George Golumbeski, Independent Director | ||
| Terrence Kearney, Director | ||
| Karen Smith, Director | ||
| Todd James, IR Contact Officer | ||
| Sujay Kango, Chief Commercial Officer | ||
| Kevin McLaughlin, CFO, Sr. VP and Treasurer | ||
| Joseph Zakrzewski, Independent Director | ||
| Habib Dable, President CEO, Director |
Acceleron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acceleron Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -29.16 | |||
| Return On Asset | -16.73 | |||
| Profit Margin | (158.11) % | |||
| Operating Margin | (158.79) % | |||
| Current Valuation | 6.93 B | |||
| Shares Outstanding | 60.7 M | |||
| Shares Owned By Insiders | 11.86 % | |||
| Shares Owned By Institutions | 90.60 % | |||
| Number Of Shares Shorted | 2.12 M | |||
| Price To Earning | (14.74) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Acceleron Stock
If you are still planning to invest in Acceleron Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acceleron Pharma's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |